News

OxyDial measures the true oxygen dissociation curve (ODC), point by point, exactly as it exists in the sample. This is not an inferred curve, not a reconstructed shape, and not …

The oxygen-hemoglobin dissociation curve (ODC) defines how blood loads oxygen in the lungs and releases it into tissue. It is one of the most fundamental measurements in physiology – and …

Researchers at the University of Illinois Chicago, have received a $3.78 million federal grant to study whether empagliflozin, a diabetes medication, can slow kidney damage in people with sickle cell …

An international research team led by the University of Zurich has published promising Phase II data for memantine, a long-approved, off-patent Alzheimer’s drug produced by AbbVie, in the treatment of …

New Phase 3 data released by HUTCHMED from the China-based ESLIM-02 trial shows that sovleplenib achieved a durable hemoglobin response in patients with warm antibody autoimmune hemolytic anemia (wAIHA), a …

New data presented by AyrmidPharma at #ASH2025 indicates that motixafortide (APHEXDA®) can robustly mobilize the hematopoietic stem cells (HSCs) required for gene therapies in sickle cell disease (SCD). The Phase …

The U.S. FDA has approved Agios Pharmaceuticals‘ AQVESME™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia. This approval, based on the positive Phase 3 ENERGIZE and …

New Phase 1b data from Fulcrum Therapeutics suggest that higher doses of the investigational oral therapy pociredir may offer greater benefits for adults with sickle cell disease (SCD). In the …

New clinical data from Ayrmid highlight a promising advance in stem cell mobilization for people with SCD pursuing gene therapy. In a first-in-human trial, the CXCR4 inhibitor motixafortide, alone and …